Breaking News Instant updates and real-time market news.

SYRS

Syros Pharmaceuticals

$7.01

0.15 (2.19%)

08:41
05/07/19
05/07
08:41
05/07/19
08:41

Syros announces new publlication highlighting discovery of SY-1365

Syros Pharmaceuticals announced the online publication of a new manuscript, Discovery and Characterization of SY-1365, a Selective, Covalent Inhibitor of CDK7, in the American Association for Cancer Research's journal, Cancer Research. SY-1365, a first-in-class selective cyclin-dependent kinase 7 inhibitor, is currently being investigated in a Phase 1 clinical trial as a single agent and in combination with standard-of-care therapies in multiple ovarian and breast cancer patient populations that lack effective treatment options. This publication highlights the discovery, mechanism of action and promise of SY-1365 as a new targeted approach for a range of difficult-to-treat cancers. Syros is currently conducting a Phase 1 clinical trial assessing the safety and efficacy of SY-1365 as a single agent and in combination with standard-of-care therapies in multiple ovarian and breast cancer patient populations. The trial includes cohorts evaluating SY-1365 as a single agent in patients with relapsed ovarian clear cell cancer and in high-grade serous ovarian cancer patients who have had three or more prior lines of therapy; in combination with carboplatin in HGSOC patients who have had one or more prior lines of therapy; in combination with fulvestrant in metastatic hormone receptor-positive breast cancer patients who are resistant to treatment with a CDK4/6 inhibitor; and as a single agent in patients with solid tumors of any histology accessible for biopsy. CDK7 plays a key role in the transcription of genes and in cell cycle regulation, and inhibiting CDK7 disrupts two important processes that cancer cells use to survive: 1) expression of cancer-promoting genes; and 2) uncontrolled cell cycle progression. SY-1365 has shown anti-tumor activity in preclinical models of a range of solid tumors and blood cancers, including cancers that have become resistant to treatment with existing therapies or where existing options have failed to provide meaningful benefit to patients. Further, data suggests that SY-1365 works to inhibit the growth of cell lines representing many different cancer types at nanomolar concentrations, decreases MCL1 protein levels, and demonstrates activity among cancer cells with low BCL-XL expression. Syros is advancing SY-5609, a highly selective and potent oral CDK7 inhibitor, toward clinical development. In preclinical studies, SY-5609 has demonstrated substantial anti-tumor activity, including inducing complete regressions in cell line-derived xenograft models of breast and ovarian cancers. The company plans to complete investigational new drug application -enabling studies by the end of 2019 to support the initiation of a Phase 1 oncology trial in early 2020.

  • 07

    May

SYRS Syros Pharmaceuticals
$7.01

0.15 (2.19%)

02/14/19
OPCO
02/14/19
INITIATION
Target $13
OPCO
Outperform
Syros Pharmaceuticals assumed with an Outperform at Oppenheimer
Oppenheimer analyst Mark Breidenbach assumed coverage of Syros Pharmaceuticals with an Outperform rating and a $13 price target. The analyst believes the company's lead program, SY-1425, has demonstrated compelling clinical proof-of-concept in a biomarker-defined population of acute myeloid leukemia patients and has an opportunity for approval in multiple therapeutic settings. However, recent changes in the AML competitive landscape, such as the approval of venetoclax, could limit uptake and prolong development timelines relative to previous estimates, he contends. Nonetheless, Breidenbach sees SY-1425 + azacitidine as a promising combination therapy in AML and expects the company to announce updated development plans in early 2019.
03/08/19
JMPS
03/08/19
INITIATION
Target $18
JMPS
Outperform
Syros Pharmaceuticals initiated with an Outperform at JMP Securities
JMP Securities transferred coverage of Syros Pharmaceuticals to analyst Jason Butler, who established an Outperform rating and $18 price target on the stock. He believes the company's recently updated clinical development strategies can provide faster paths to market and maximize commercial potential for SY-1425 and SY-1365, Butler tells investors.
03/08/19
03/08/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Tilray (TLRY) initiated with an Underperform at Jefferies. 2. BB&T (BBT) initiated with a Buy at Odeon Capital. 3. Syros Pharmaceuticals (SYRS) initiated with an Outperform at JMP Securities. 4. W&T Offshore (WTI) initiated with a Buy at Stifel. 5. Ichor Holdings (ICHR) initiated with a Buy at DA Davidson. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
04/10/19
PIPR
04/10/19
NO CHANGE
Target $24
PIPR
Overweight
Syros Pharmaceuticals price target lowered to $24 from $28 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff lowered his price target for Syros Pharmaceuticals to $24 from $28 to account for dilution of the company's recent $70M capital raise. The analyst, however, reiterates an Overweight rating on the name. Syros is developing potentially best-in-class CDK7 inhibitors, Tenthoff tells investors in a research note. He points out that data from the expansion cohorts in ovarian cancer are expected in Q4.

TODAY'S FREE FLY STORIES

ABMD

Abiomed

$260.47

7.89 (3.12%)

05:10
05/22/19
05/22
05:10
05/22/19
05:10
Hot Stocks
Abiomed says FDA confirmed Impella RP heart pump is 'safe and effective' »

Abiomed yesterday …

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jun

  • 13

    Nov

ABMD

Abiomed

$260.47

7.89 (3.12%)

05:08
05/22/19
05/22
05:08
05/22/19
05:08
Hot Stocks
FDA says benefits of Impella RP system continue to outweigh risks »

The FDA told doctors in a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jun

  • 13

    Nov

FLIR

Flir Systems

$49.66

0.65 (1.33%)

05:02
05/22/19
05/22
05:02
05/22/19
05:02
Upgrade
Flir Systems rating change  »

Flir Systems upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jun

  • 27

    Jun

TMDI

Titan Medical

$2.70

0.2 (8.00%)

04:59
05/22/19
05/22
04:59
05/22/19
04:59
Initiation
Titan Medical initiated  »

Titan Medical initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRXC

TransEnterix

$1.27

-0.03 (-2.32%)

04:57
05/22/19
05/22
04:57
05/22/19
04:57
Initiation
TransEnterix initiated  »

TransEnterix initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

04:55
05/22/19
05/22
04:55
05/22/19
04:55
General news
Breaking General news story  »

Week of 5/17 MBA Mortgage…

PFG

Principal Financial

$55.31

0.41 (0.75%)

04:55
05/22/19
05/22
04:55
05/22/19
04:55
Conference/Events
Principal Financial Group participates in a conference call with JPMorgan »

Life Insurance Analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 11

    Jun

  • 26

    Jul

STML

Stemline

$15.07

0.71 (4.94%)

04:55
05/22/19
05/22
04:55
05/22/19
04:55
Conference/Events
Stemline management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 31

    May

ARKAY

Arkema

$0.00

(0.00%)

, AVT

Avnet

$43.94

0.84 (1.95%)

04:55
05/22/19
05/22
04:55
05/22/19
04:55
Conference/Events
Lightfair International to hold a conference »

Lightfair 2019…

ARKAY

Arkema

$0.00

(0.00%)

AVT

Avnet

$43.94

0.84 (1.95%)

CREE

Cree

$58.84

1.41 (2.46%)

ETN

Eaton

$79.88

1.39 (1.77%)

IKTSY

Intertek

$0.00

(0.00%)

ITRI

Itron

$57.78

1.21 (2.14%)

ORCL

Oracle

$54.18

0.54 (1.01%)

SSNLF

Samsung

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 04

    Jun

  • 10

    Jun

  • 20

    Aug

04:55
05/22/19
05/22
04:55
05/22/19
04:55
Conference/Events
Credit Suisse U.S. strategist team to hold an analyst/industry conference call »

The U.S. Sector…

MED

Medifast

$146.66

1.35 (0.93%)

04:55
05/22/19
05/22
04:55
05/22/19
04:55
Conference/Events
Medifast management to meet with Sidoti »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 12

    Jun

EXTR

Extreme Networks

$6.15

0.11 (1.82%)

04:55
05/22/19
05/22
04:55
05/22/19
04:55
Conference/Events
JPMorgan telecom/IT hardware analyst to hold an analyst/industry conference call »

Telecom & IT Hardware…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 28

    May

  • 30

    May

BANR

Banner Corp.

$53.76

-0.04 (-0.07%)

04:55
05/22/19
05/22
04:55
05/22/19
04:55
Conference/Events
Banner Corp. management to meet with Sandler ONeill »

Meeting to be held in Los…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 04

    Jun

CHD

Church & Dwight

$73.99

-0.02 (-0.03%)

04:55
05/22/19
05/22
04:55
05/22/19
04:55
Conference/Events
Church & Dwight management to meet with SunTrust »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

MSM

MSC Industrial

$75.80

0.57 (0.76%)

04:55
05/22/19
05/22
04:55
05/22/19
04:55
Conference/Events
MSC Industrial management to meet with William Blair »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 23

    May

  • 24

    May

  • 05

    Jun

  • 13

    Nov

KLIC

Kulicke & Soffa

$19.35

0.19 (0.99%)

04:55
05/22/19
05/22
04:55
05/22/19
04:55
Conference/Events
Kulicke & Soffa management to meet with Craig-Hallum »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

CINF

Cincinnati Financial

$99.25

1.07 (1.09%)

04:55
05/22/19
05/22
04:55
05/22/19
04:55
Conference/Events
Cincinnati Financial management to meet with MKM Partners »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

JAZZ

Jazz Pharmaceuticals

$139.92

1.49 (1.08%)

04:55
05/22/19
05/22
04:55
05/22/19
04:55
Conference/Events
Jazz Pharmaceuticals management to meet with Piper Jaffray »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 23

    May

  • 31

    May

  • 05

    Jun

  • 23

    Jun

HALO

Halozyme

$15.60

0.385 (2.53%)

04:55
05/22/19
05/22
04:55
05/22/19
04:55
Conference/Events
Halozyme management to meet with JMP Securities »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 23

    May

  • 31

    May

DENN

Denny's

$19.62

-0.03 (-0.15%)

04:55
05/22/19
05/22
04:55
05/22/19
04:55
Conference/Events
Denny's management to meet with Stephens »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 18

    Jun

  • 13

    Nov

STAY

Extended Stay America

$17.92

0.24 (1.36%)

04:55
05/22/19
05/22
04:55
05/22/19
04:55
Conference/Events
Extended Stay America management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 30

    May

04:55
05/22/19
05/22
04:55
05/22/19
04:55
General news
Breaking General news story  »

New York Federal Reserve…

GWR

Genesee & Wyoming

$85.81

0.505 (0.59%)

, HA

Hawaiian Holdings

$26.82

0.37 (1.40%)

04:55
05/22/19
05/22
04:55
05/22/19
04:55
Conference/Events
Wolfe Research to hold a conference »

12th Annual Global…

GWR

Genesee & Wyoming

$85.81

0.505 (0.59%)

HA

Hawaiian Holdings

$26.82

0.37 (1.40%)

AAL

American Airlines

$31.29

0.33 (1.07%)

UAL

United Continental

$82.94

1.22 (1.49%)

ALGT

Allegiant Travel

$146.16

4.21 (2.97%)

SAVE

Spirit Airlines

$48.80

1.75 (3.72%)

CVTI

Covenant Transportation

$17.05

-0.21 (-1.22%)

VST

Vistra Energy

$25.75

0.69 (2.75%)

WAB

Wabtec

$64.63

0.25 (0.39%)

R

Ryder

$58.09

0.7 (1.22%)

XPO

XPO Logistics

$57.86

0.865 (1.52%)

MATX

Matson

$39.20

-0.51 (-1.28%)

NCLH

Norwegian Cruise Line

$56.79

0.86 (1.54%)

DAL

Delta Air Lines

$54.84

0.56 (1.03%)

CPA

Copa Holdings

$91.97

0.51 (0.56%)

NSC

Norfolk Southern

$204.63

0.03 (0.01%)

CSX

CSX

$78.33

0.24 (0.31%)

ECHO

Echo Global

$21.35

-0.04 (-0.19%)

LUV

Southwest

$53.37

1.37 (2.63%)

HD

Home Depot

$191.41

0.54 (0.28%)

TGT

Target

$72.05

-0.05 (-0.07%)

JBHT

J.B. Hunt

$95.72

-1.76 (-1.81%)

HUBG

Hub Group

$41.29

0.61 (1.50%)

BASFY

BASF

$0.00

(0.00%)

UPS

UPS

$99.40

0.89 (0.90%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 22

    May

  • 22

    May

  • 22

    May

  • 23

    May

  • 23

    May

  • 23

    May

  • 29

    May

  • 05

    Jun

  • 05

    Jun

  • 12

    Jun

  • 12

    Jun

  • 12

    Jun

  • 13

    Jun

  • 14

    Jun

  • 18

    Jun

  • 20

    Jun

  • 24

    Jul

  • 25

    Jul

  • 30

    Jul

  • 13

    Nov

04:55
05/22/19
05/22
04:55
05/22/19
04:55
Conference/Events
JMP Securities to hold a field trip »

Bermuda (Re)Insurance…

EVOP

EVO Payments

$28.66

0.41 (1.45%)

, WEX

Wex

$204.86

3.21 (1.59%)

04:55
05/22/19
05/22
04:55
05/22/19
04:55
Conference/Events
Barclays to hold a forum »

Emerging Payments Forum…

EVOP

EVO Payments

$28.66

0.41 (1.45%)

WEX

Wex

$204.86

3.21 (1.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

  • 29

    May

  • 05

    Jun

  • 11

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.